Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2478 2024-03-03 22:58:12 |
2 format correct Meta information modification 2478 2024-03-04 08:57:16 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Woronkowicz, M.; Roberts, H.; Skopiński, P. Insulin-like Growth Factor (IGF) System in Corneal Epithelium. Encyclopedia. Available online: https://encyclopedia.pub/entry/55791 (accessed on 15 April 2024).
Woronkowicz M, Roberts H, Skopiński P. Insulin-like Growth Factor (IGF) System in Corneal Epithelium. Encyclopedia. Available at: https://encyclopedia.pub/entry/55791. Accessed April 15, 2024.
Woronkowicz, Małgorzata, Harry Roberts, Piotr Skopiński. "Insulin-like Growth Factor (IGF) System in Corneal Epithelium" Encyclopedia, https://encyclopedia.pub/entry/55791 (accessed April 15, 2024).
Woronkowicz, M., Roberts, H., & Skopiński, P. (2024, March 03). Insulin-like Growth Factor (IGF) System in Corneal Epithelium. In Encyclopedia. https://encyclopedia.pub/entry/55791
Woronkowicz, Małgorzata, et al. "Insulin-like Growth Factor (IGF) System in Corneal Epithelium." Encyclopedia. Web. 03 March, 2024.
Insulin-like Growth Factor (IGF) System in Corneal Epithelium
Edit

The corneal epithelium, comprising three layers of cells, represents the outermost portion of the eye and functions as a vital protective barrier while concurrently serving as a critical refractive structure. Maintaining its homeostasis involves a complex regenerative process facilitated by the functions of the lacrimal gland, tear film, and corneal nerves. Crucially, limbal epithelial stem cells located in the limbus (transitional zone between the cornea and the conjunctiva) are instrumental for the corneal epithelium integrity by replenishing and renewing cells. Re-epithelialization failure results in persistent defects, often associated with various ocular conditions including diabetic keratopathy. The insulin-like growth factor (IGF) system is a sophisticated network of insulin and other proteins essential for numerous physiological processes.

limbal epithelial stem cells insulin-like growth factor system insulin IGF-1 IGF-2 IGFBP corneal epithelium diabetes

1. Introduction

The corneal epithelium is the outermost part of the cornea and consists of three cellular layers: the superficial layer, middle wing layer, and the innermost basal cell layer with Bowman’s membrane in humans separating it from the corneal stroma [1]. It plays the role of a protective barrier as well as a refractive structure due to its avascular character. Its homeostasis is maintained through a complex regenerative process which takes about 10 days and involves proliferation and migration of epithelial cells [2]. In addition, the lacrimal gland function, tear film, and corneal nerves are pivotal in maintaining the health and integrity of the corneal epithelium [3].
The insulin-like growth factor (IGF) system is a complex network of hormones and proteins that play crucial roles in cell growth, development, and metabolism [4]. It consists of insulin, insulin-like growth factor 1 and -2 (IGF-1, IGF-2), their receptors: insulin receptor (INSR), IGF type 1 and 2 receptors (IGF-1R, IGF-2R), as well as several IGF-binding proteins (IGFBPs), Figure 1.
Figure 1. Schematic diagram of the IGF system.

2. The Role of Insulin and Effect of Diabetes

Insulin is a polypeptide hormone consisting of two A and two B chains, produced by pancreatic beta cells and secreted in response to a high blood glucose level [4]. It has metabolic effects and plays a role in various phases of the cell cycle, from growth to apoptosis. The presence of INSR in the cornea was first demonstrated by Naeser [5]. Alternative splicing of INSR occurs at exon 11, leading to the generation of two distinct isoforms: INSRA and INSRB [4]. An immunohistochemical analysis by Rocha et al. demonstrated that INSR is expressed in the corneal epithelium [6]. In their study of human corneas, INSR was predominantly localized within the cytoplasm and plasma membrane in the wing and superficial cell layers, with noticeable variability in its expression across the basal and intermediate suprabasal cells (Table 1).
Table 1. Summary of the IGF system receptors and their localization in the corneal epithelium.
Receptor Localization Ref.
Insulin receptor Plasma membrane and cytoplasm; mainly in the wing and superficial cell layers [6]
  Nucleus [7]
  Mitochondria [8]
IGF-1R All layers of the cornea; mainly around cellular nuclei of actively differentiating epithelial cells [7]
  Plasma membrane and cytoplasm [6]
  Mitochondria [8]
Hybrid- R Plasma membrane and nucleus [9]
IGF-2R Central and peripheral epithelium with higher expression in the periphery following corneal injury [10]
  Primarily in the basal corneal epithelium in murine and porcine corneas [11]
Diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia, results from a deficiency in insulin secretion, impaired insulin action, or a combination of both [12]. The two primary forms of diabetes, type 1 and type 2, differ in their pathophysiology but share the common feature of dysregulated glucose metabolism. In type 1 diabetes, an autoimmune response leads to the destruction of pancreatic beta cells, resulting in insufficient insulin production, while type 2 diabetes involves a combination of insulin resistance and relative insulin deficiency. Diabetes can significantly impact the eye, including the ocular surface, leading to dysfunction of epithelium and development of diabetic keratopathy.
Unlike most tissues, where insulin stimulates glucose uptake through the glucose transporter-4 (GLUT4), corneal epithelium is insulin-independent [13]. Glucose uptake in epithelial cells occurs through constitutively active glucose transporters, GLUT1, which undergo upregulation in case of a high metabolic demand, such as wound healing, similarly in diabetic and non-diabetic corneas.
Culture studies with human corneal epithelial cells demonstrated that insulin induces phosphorylation of extracellular signal regulated kinase (ERK 1/2), PI3-kinase [14] and epidermal growth factor receptor (EGFR), thereby promoting cell migration and wound healing [15]. Interestingly, increased expression of PI3K pathway kinases occurs in canine corneal cells following insulin treatment, contrasting with the observed lack of analogous effects in vitro in human corneal cells [16]. Within the corneal epithelium, insulin influences PTEN-induced kinase 1 (PINK-1)-mediated mitophagy and the mitochondrial accumulation of insulin receptor (INSR). Interactions between INSR and the voltage-dependent anion channel-1 (VDAC1) prevent fragmentation and altered polarization of mitochondria, as well as facilitate PINK-1-mediated mitophagy [8]. In diabetic rats, the process of histone H3 acetylation is reduced in corneal epithelial cells, resulting in compacted chromatin organization in nuclei characterized by increased size and elevated DNA ploidy [17].
A study by Song et al. showed that insulin can normalize the circadian rhythm of corneal cell mitosis via five main clock genes (Clock, Bmal1, Per2, Cry1, and Rev-erbα) whose expression is affected in diabetes [18]. Moreover, innate-like lymphocytes, such as γ δ T-cells expressing chemotactic factor IL-17 for neutrophils and monocytes, were found to be recruited to the corneal limbus in a diurnal pattern. In diabetes, the limbal cell migration is increased, potentially leading to the inflammatory state delaying wound healing, but is restored upon systemic insulin administration.
Insulin is secreted from the lacrimal gland and present in the tear film at a mean concentration of 0.404 ± 0.129 ng/mL, which is reduced in fasted individuals and shows no difference related to gender [6]. In diabetes, its secretion is reduced due to damage to the lacrimal gland and reduced corneal sensation, caused by hyperglycemia and oxidative stress [19]. In rat models of diabetes, histological analysis showed an increased lipofuscin level and higher malonaldehyde as well as peroxidase activity in the lacrimal glands compared to healthy animals [20]. Insulin signaling in rat lacrimal glands becomes impaired in the fourth week of diabetes, with the lacrimal gland serving as an extra pancreatic source of insulin for at least 4–7 weeks [21][22].
Several studies reported ocular surface abnormalities in patients with diabetes, such as reduced tear breakup time, lower tears secretion, and increased level of inflammatory markers: NPY, STAT-5 ICAM-1, and TNF-α [23][24][25]. Clinically, diabetic ocular surface complications include reduced corneal sensitivity and delayed epithelialization leading to dry eye syndrome, punctate corneal epitheliopathy, recurrent erosions, persistent epithelial defects, and neurotrophic keratopathy [19][26]. On a histological level, reduction in basal epithelial cell density and size, and increased intercellular space as well as increased corneal epithelial basement membrane thickness and irregularity were demonstrated in diabetic corneas [27][28][29][30][31]. It is postulated that diabetic ocular changes might be in part explained by the dysregulation of a pathway involving the opioid growth factor (OGF), i.e., [Met5]- enkephalin binding to nuclear-associated receptor (OGFr) [32]. In diabetes, serum OGF levels are elevated, and insulin may affect the OGF-OGFr axis [26][33][34].
A fundamentally negative impact of diabetes on the corneal epithelium is closely linked to its effect on LESC functioning [35]. A significant reduction in Palisades of Vogt in all four limbus quadrants was demonstrated in patients with type 2 diabetes using in vivo confocal microscopy [36]. In the same study, a higher risk of stem cell damage was noted in those with a high-density lipoprotein, triglycerides, and total cholesterol level above 1.215 mmol/L, 1.59 mmol/L, and 4.75 mmol/L, respectively.
Immunohistochemistry analysis of corneas from diabetic patients revealed a reduction in putative limbal stem cell markers, including ATP-binding cassette superfamily G member 2 protein (ABCG2), N-cadherin, ΔNp63α, K15, K17, K19, and β1 integrin [37]. This decrease in marker expression was associated with lower immunoreactivity and a diminished number of detected cells, indicating potential depletion or dysfunction of LESCs. Moreover, the ex vivo diabetic limbus was characterized by irregular epithelial basement membrane and reduced expression of laminin γ3 and fibronectin.
In another study, a reduction in expression of putative stem cell markers K15 and ΔNp63α was demonstrated in limbal epithelial stem cell (LESC)-enriched cultures obtained from the corneoscleral rims in diabetic patients with changes reversed by adenoviral gene therapy [38]. In an animal model of type 2 diabetes, reduced expression of corneal stem/progenitor cell markers, including Hes1, Keratin15, and p75, was observed in mice corneas [39]. Similarly, in mice with type 1 diabetes, the expression of putative LESC markers K15, ∆Np63α, and glycoprotein hormone alpha-2 (GPHA2) was reduced in the limbus [40].
A study employing a new method of objective quantification of immunofluorescence, aiming to overcome limitations of manual grading, observed a reduction in the putative LESC marker K14 in the limbus of diabetic mice [35]. Furthermore, reduced expression of putative limbal epithelial stem cell markers, such as paired box protein-6 (PAX6), ∆Np63α, K15, K17, and membrane transporter ABCG2, was demonstrated in cultured diabetic human limbal epithelial cells, which was associated with slower corneal epithelial wound healing [41]. It is crucial to note, however, that several cell markers for LESCs can also be identified in other parts of the eye, and their use has limitations in discriminating pure stem cells from early transient amplifying cells [35][42].
The nervous system plays an instrumental role in maintaining the homeostasis of the corneal epithelium. Nerve branches of the sub-basal corneal nerve plexus are considered an important source of substances contributing to ocular surface health. Importantly, corneal innervation impacts a stem cells niche [43], with a limbal stem cells reduction reported following the destruction of the ophthalmic branch of the trigeminal nerve [39].
Detrimental effects of diabetes on corneal sensitivity, nerve fiber length, and density in both humans [44][45][46][47][48] and animals [39][49][50][51][52][53][54] have been reported in numerous studies and reviewed elsewhere [55][56][57]. Recently, a 3D tissue model of the human cornea was employed to demonstrate the degenerative effects of hyperglycemia on corneal nerves [58]. On a cellular level, pannexin1 channels present in corneal synaptosomes were found to be more glycosylated, characterized by enhanced membrane localization and leading to increased ATP release in diabetic subjects compared to non-diabetic controls [59]. Animal studies showed that insulin stimulates corneal nerve regeneration and expression of a limbal stem cell marker (DNp63) via Wnt signaling [60], and when applied topically, it exerts neuroprotective properties in diabetic rats [52]. In patients with type 2 diabetes, a nerve regenerative process can be limited by insulin resistance [61]. Interestingly, a prediabetic state is characterized by increased parameters of intra-epithelial corneal basal nerves, which could be attributed to the neurotrophic effect of higher insulin levels [54].
MicroRNAs (miRNAs) are 18–25 nucleotides long non-coding RNAs that downregulate the expression of genes at a post-transcription level by binding complementary mRNAs [62]. They are involved in numerous cellular processes and can modulate multiple genes, making them a valuable research focus in regenerative medicine [63]. Studies suggest that they also play a role in LESC-associated processes, such as macropinocytosis, autophagy, and the expression of putative stem cell markers [64][65]. Funari at al. reported on the dysregulation of miRNA expression in human autopsy diabetic corneas, which was associated with abnormal wound healing [66]. Microarray analysis demonstrated that among the 29 miRNA studied, miR-146a, 21, and 424 were the most upregulated, while miR-509-3p and 143 were expressed at the lowest level. This is in line with other reports, which indicate that overexpression of miR-146a in the diabetic limbus may result in a reduced corneal inflammatory and healing response [35][67][68]. In another study, genome-wide sequencing was applied, identifying differences in expression profiles of 20 miRNA between normal and diabetic human corneas [69]. Results showed that miR-10b was upregulated in the diabetic limbus, with a higher increase observed in type 1 compared to type 2 diabetes. Moreover, altered expression of miRNA in exosomes have been demonstrated in diabetic limbal stem cells [70].
Overall, diabetes may affect the function of LESCs through various mechanisms and can potentially lead to severe, persistent corneal erosions. However, despite the detrimental effect on the cornea, the limbal barrier tends to be preserved, with no development of conjunctivalization or neovascularization characteristic for limbal stem cell deficiency [35].
Animal studies have demonstrated the beneficial effect of insulin treatment on epithelial wound healing in diabetic animals [71][72]. Klocek et al. found that corneal abrasions in type 1 diabetic mice, treated with topical insulin, reduced in size by 29% compared to the controls after 16 h [71]. Moreover, Zagon et al. reported a comparable rate of corneal healing in diabetic rats with an insulin implant and normal animals [72].
The first therapeutic use of topical insulin in humans was described by Aynsely in 1945 in a case series of patients with corneal ulcers [73]. Successful treatment with topical insulin for corneal conditions involving the epithelium has also been reported in subsequent studies summarized in Table 2.
Table 2. Published studies evaluating results of a treatment of corneal conditions with epithelial defects with a topical insulin.
Ref. Study Design Diagnosis No. of Eyes Mean Age
(Years)
Eyes with Complete Epithelialization (%) Mean Time to Epithelialization
(Days)
[74] Randomized controlled trial Postoperative corneal epithelial defect after vitreoretinal surgery in diabetics A—8
B—8
C—8
A—62.62 ± 5.99
B—56.12 ± 7.77
C—55.75 ± 6.64
A—100
B—100
C—100
All eyes healed within 6 days
100% eyes in A, 75% eyes in B and 62.5% eyes in C group healed within 3 days.
[75] Randomized clinical trial Postoperative corneal epithelial defects after vitreoretinal surgery 19 57.05 ± 12.33 100 3
[76] Prospective interventional, single-center case series Refractory persistent epithelial defects 11 45.4 ± 25 82 62.3 ± 34.6
[77] Prospective non-randomized hospital-based study Refractory persistent epithelial defects 21 72.2 81 34.8 ± 29.9
[78] Prospective non-randomized hospital-based study Recurrent epithelial erosions 15 29.00 ± 8.72 100 21
[79] Retrospective, observational Refractory neurotrophic keratopathy (NK) in stages 2 and 3 21 61 90 18 ± 9 in NK stage 2; 29 ± 11 in NK stage 3
[80] Retrospective, consecutive case–control series Refractory persistent epithelial defects 61 71.5 ± 19.3 84 32.6 ± 28.3
[81] Retrospective
case series
Refractory neurotrophic corneal ulcers 6 36.5 100 7 to 25
[82] Retrospective
Case series
Corneal epithelial erosions induced during vitreoretinal surgery in diabetics 5 49 100 2.5 ± 0.6
[83] Retrospective case series Dry eye disease 32 61.3 ± 16.8 - -
[84] Case report Corneal ulcer following chemical injury 1 41 100 60
[85] Case report Bilateral Neurotrophic keratitis 2 55 100 7
[86] Case report Neurotrophic keratopathy after resection of acoustic neuroma 1 45 100 14
[87] Case report Neurotrophic keratopathy 1 40 100 20
[88] Case report Neurotrophic keratopathy 1 64 100 30
A—eyes treated with topical insulin 0.5 unit QID, B—eyes treated with topical insulin 1 unit QID, C—eyes treated with topical insulin 2 units QID.
Interestingly, a recent culture study with ocular surface cells showed that drops from plasma rich in growth factors were superior to topical insulin at two different concentrations (1 and 0.2 IU/m) in promoting wound healing and reducing the fibrosis process [89]. Currently, no universal protocol exists regarding treatment with topical insulin, as studies apply different preparation methods, dosages, concentrations, and types of drops [90][91].
Several studies have demonstrated novel ways of delivering insulin to the eye. A new delivery system, containing chitosan/poloxamer gel loaded with chitosan microparticles, has been reported to increase the local bioavailability of topical insulin in the treatment of the ocular surface in diabetic rats [92]. Additionally, electrospun fiber mats were shown to be effective in delivering insulin to the porcine cornea [93]. Recently, a convolutional neural network statistical analysis was applied to demonstrate the therapeutic effect of insulin liposomes on corneal epithelial defects in rats [94]. In a study of alkali-burned corneal models, a nano-system combining liposomes and trimethyl chitosan was used to deliver insulin and vascular endothelial growth factor small interfering RNA [95]. This combined therapy proved effective in reducing oxidative stress, increasing epithelialization, and inhibiting corneal neovascularization. Metabolomic analysis demonstrated that the therapeutic effect was possibly linked to insulin inhibiting the ferroptosis signaling pathway.

References

  1. Vaidyanathan, U.; Hopping, G.C.; Liu, H.Y.; Somani, A.N.; Ronquillo, Y.C.; Hoopes, P.C.; Moshirfar, M. Persistent Corneal Epithelial Defects: A Review Article. Med. Hypothesis Discov. Innov. Ophthalmol. J. 2019, 8, 163–176.
  2. Tarvestad-Laise, K.E.; Ceresa, B.P. Modulating Growth Factor Receptor Signaling to Promote Corneal Epithelial Homeostasis. Cells 2023, 12, 2730.
  3. Stuard, W.L.; Titone, R.; Robertson, D.M. IGFBP-3 Functions as a Molecular Switch That Mediates Mitochondrial and Metabolic Homeostasis. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2022, 36, e22062.
  4. Stuard, W.L.; Titone, R.; Robertson, D.M. The IGF/Insulin-IGFBP Axis in Corneal Development, Wound Healing, and Disease. Front. Endocrinol. 2020, 11, 24.
  5. Naeser, P. Insulin Receptors in Human Ocular Tissues. Immunohistochemical Demonstration in Normal and Diabetic Eyes. Ups. J. Med. Sci. 1997, 102, 35–40.
  6. Rocha, E.M.; Cunha, D.A.; Carneiro, E.M.; Boschero, A.C.; Saad, M.J.A.; Velloso, L.A. Identification of Insulin in the Tear Film and Insulin Receptor and IGF-1 Receptor on the Human Ocular Surface. Investig. Ophthalmol. Vis. Sci. 2002, 43, 963–967.
  7. Robertson, D.M.; Zhu, M.; Wu, Y.-C. Cellular Distribution of the IGF-1R in Corneal Epithelial Cells. Exp. Eye Res. 2012, 94, 179–186.
  8. Titone, R.; Robertson, D.M. Insulin Receptor Preserves Mitochondrial Function by Binding VDAC1 in Insulin Insensitive Mucosal Epithelial Cells. FASEB J. 2020, 34, 754–775.
  9. Wu, Y.-C.; Zhu, M.; Robertson, D.M. Novel Nuclear Localization and Potential Function of Insulin-like Growth Factor-1 Receptor/Insulin Receptor Hybrid in Corneal Epithelial Cells. PLoS ONE 2012, 7, e42483.
  10. Jiang, Y.; Ju, Z.; Zhang, J.; Liu, X.; Tian, J.; Mu, G. Effects of Insulin-like Growth Factor 2 and Its Receptor Expressions on Corneal Repair. Int. J. Clin. Exp. Pathol. 2015, 8, 10185–10191.
  11. Bohnsack, R.N.; Warejcka, D.J.; Wang, L.; Gillespie, S.R.; Bernstein, A.M.; Twining, S.S.; Dahms, N.M. Expression of Insulin-like Growth Factor 2 Receptor in Corneal Keratocytes during Differentiation and in Response to Wound Healing. Investig. Ophthalmol. Vis. Sci. 2014, 55, 7697–7708.
  12. Tests, D.; Diabetes, F.O.R. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2015, 38, S8–S16.
  13. Takahashi, H.; Ohara, K.; Ohmura, T.; Takahashi, R.; Zieske, J.D. Glucose Transporter 1 Expression in Corneal Wound Repair under High Serum Glucose Level. Jpn. J. Ophthalmol. 2000, 44, 470–474.
  14. Shanley, L.J.; McCaig, C.D.; Forrester, J.V.; Zhao, M. Insulin, Not Leptin, Promotes in Vitro Cell Migration to Heal Monolayer Wounds in Human Corneal Epithelium. Investig. Ophthalmol. Vis. Sci. 2004, 45, 1088–1094.
  15. Lyu, J.; Lee, K.-S.; Joo, C.-K. Transactivation of EGFR Mediates Insulin-Stimulated ERK1/2 Activation and Enhanced Cell Migration in Human Corneal Epithelial Cells. Mol. Vis. 2006, 12, 1403–1410.
  16. Peterson, C.; Chandler, H.L. Insulin Facilitates Corneal Wound Healing in the Diabetic Environment through the RTK-PI3K/Akt/MTOR Axis in Vitro. Mol. Cell. Endocrinol. 2022, 548, 111611.
  17. Herencia-Bueno, K.E.; Aldrovani, M.; Crivelaro, R.M.; Thiesen, R.; Barros-Sobrinho, A.A.F.; Claros-Chacaltana, F.D.Y.; Padua, I.R.M.; Santos, D.M.; Laus, J.L. Reduction in Histone H3 Acetylation and Chromatin Remodeling in Corneas of Alloxan-Induced Diabetic Rats. Cornea 2018, 37, 624–632.
  18. Song, F.; Xue, Y.; Dong, D.; Liu, J.; Fu, T.; Xiao, C.; Wang, H.; Lin, C.; Liu, P.; Zhong, J.; et al. Insulin Restores an Altered Corneal Epithelium Circadian Rhythm in Mice with Streptozotocin-Induced Type 1 Diabetes. Sci. Rep. 2016, 6, 32871.
  19. de Cássia Alves, M.; Carvalheira, J.B.; Módulo, C.M.; Rocha, E.M. Tear Film and Ocular Surface Changes in Diabetes Mellitus. Arq. Bras. Oftalmol. 2008, 71, 96–103.
  20. Módulo, C.M.; Jorge, A.G.; Dias, A.C.; Braz, A.M.; Bertazolli-Filho, R.; Jordão, A.A.J.; Sérgio Marchini, J.; Rocha, E.M. Influence of Insulin Treatment on the Lacrimal Gland and Ocular Surface of Diabetic Rats. Endocrine 2009, 36, 161–168.
  21. Cunha, D.A.; de Alves, M.C.; Stoppiglia, L.F.; Jorge, A.G.; Módulo, C.M.; Carneiro, E.M.; Boschero, A.C.; Saad, M.J.A.; Velloso, L.A.; Rocha, E.M. Extra-Pancreatic Insulin Production in RAt Lachrymal Gland after Streptozotocin-Induced Islet Beta-Cells Destruction. Biochim. Biophys. Acta 2007, 1770, 1128–1135.
  22. Rocha, E.M.; Lima, M.H.d.M.; Carvalho, C.R.; Saad, M.J.; Velloso, L.A. Characterization of the Insulin-Signaling Pathway in Lacrimal and Salivary Glands of Rats. Curr. Eye Res. 2000, 21, 833–842.
  23. Di Zazzo, A.; Coassin, M.; Micera, A.; Mori, T.; De Piano, M.; Scartozzi, L.; Sgrulletta, R.; Bonini, S. Ocular Surface Diabetic Disease: A Neurogenic Condition? Ocul. Surf. 2021, 19, 218–223.
  24. Manchikanti, V.; Kasturi, N.; Rajappa, M.; Gochhait, D. Ocular Surface Disorder among Adult Patients with Type II Diabetes Mellitus and Its Correlation with Tear Film Markers: A Pilot Study. Taiwan J. Ophthalmol. 2021, 11, 156–160.
  25. Çakır, B.K.; Katırcıoğlu, Y.; Ünlü, N.; Duman, S.; Üstün, H. Ocular Surface Changes in Patients Treated with Oral Antidiabetic Drugs or Insulin. Eur. J. Ophthalmol. 2016, 26, 303–306.
  26. Purushothaman, I.; Zagon, I.S.; Sassani, J.W.; McLaughlin, P.J. Ocular Surface Complications in Diabetes: The Interrelationship between Insulin and Enkephalin. Biochem. Pharmacol. 2021, 192, 114712.
  27. Quadrado, M.J.; Popper, M.; Morgado, A.M.; Murta, J.N.; Van Best, J.A. Diabetes and Corneal Cell Densities in Humans by in Vivo Confocal Microscopy. Cornea 2006, 25, 761–768.
  28. Taylor, H.R.; Kimsey, R.A. Corneal Epithelial Basement Membrane Changes in Diabetes. Investig. Ophthalmol. Vis. Sci. 1981, 20, 548–553.
  29. Qu, J.H.; Li, L.; Tian, L.; Zhang, X.Y.; Thomas, R.; Sun, X.G. Epithelial Changes with Corneal Punctate Epitheliopathy in Type 2 Diabetes Mellitus and Their Correlation with Time to Healing. BMC Ophthalmol. 2018, 18, 1.
  30. Kowalczuk, L.; Latour, G.; Bourges, J.-L.; Savoldelli, M.; Jeanny, J.-C.; Plamann, K.; Schanne-Klein, M.-C.; Behar-Cohen, F. Multimodal Highlighting of Structural Abnormalities in Diabetic Rat and Human Corneas. Transl. Vis. Sci. Technol. 2013, 2, 3.
  31. Ishibashi, F.; Kawasaki, A.; Yamanaka, E.; Kosaka, A.; Uetake, H. Morphometric Features of Corneal Epithelial Basal Cells, and Their Relationship with Corneal Nerve Pathology and Clinical Factors in Patients with Type 2 Diabetes. J. Diabetes Investig. 2013, 4, 492–501.
  32. Zagon, I.S.; Sassani, J.W.; Purushothaman, I.; McLaughlin, P.J. Blockade of OGFr Delays the Onset and Reduces the Severity of Diabetic Ocular Surface Complications. Exp. Biol. Med. 2021, 246, 629–636.
  33. Zagon, I.S.; Sassani, J.W.; Purushothaman, I.; McLaughlin, P.J. Dysregulation of the OGF–OGFr Pathway Correlates with Elevated Serum OGF and Ocular Surface Complications in the Diabetic Rat. Exp. Biol. Med. 2020, 245, 1414–1421.
  34. Purushothaman, I.; Zagon, I.S.; Sassani, J.W.; Zhou, S.; McLaughlin, P.J. Sex Differences in the Magnitude of Diabetic Ocular Surface Complications: Role of Serum OGF. Physiol. Behav. 2021, 237, 113436.
  35. Nureen, L.; Di Girolamo, N. Limbal Epithelial Stem Cells in the Diabetic Cornea. Cells 2023, 12, 2458.
  36. Chen, D.; Wang, L.; Guo, X.; Zhang, Z.; Xu, X.; Jin, Z.-B.; Liang, Q. Evaluation of Limbal Stem Cells in Patients With Type 2 Diabetes: An In Vivo Confocal Microscopy Study. Cornea 2024, 43, 67–75.
  37. Saghizadeh, M.; Soleymani, S.; Harounian, A.; Bhakta, B.; Troyanovsky, S.M.; Brunken, W.J.; Pellegrini, G.; Ljubimov, A.V. Alterations of Epithelial Stem Cell Marker Patterns in Human Diabetic Corneas and Effects of C-Met Gene Therapy. Mol. Vis. 2011, 17, 2177–2190.
  38. Kramerov, A.A.; Saghizadeh, M.; Ljubimov, A.V. Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-Cultured Corneas and Limbal Epithelial Cells. J. Vis. Exp. 2016, 110, e54058.
  39. Ueno, H.; Hattori, T.; Kumagai, Y.; Suzuki, N.; Ueno, S.; Takagi, H. Alterations in the Corneal Nerve and Stem/Progenitor Cells in Diabetes: Preventive Effects of Insulin-like Growth Factor-1 Treatment. Int. J. Endocrinol. 2014, 2014, 312401.
  40. Zhang, Z.; Yang, L.; Li, Y.; Sun, D.; Chen, R.; Dou, S.; Liu, T.; Zhang, S.; Zhou, Q.; Xie, L. Interference of Sympathetic Overactivation Restores Limbal Stem/Progenitor Cells Function and Accelerates Corneal Epithelial Wound Healing in Diabetic Mice. Biomed. Pharmacother. 2023, 161, 114523.
  41. Kramerov, A.A.; Saghizadeh, M.; Maguen, E.; Rabinowitz, Y.S.; Ljubimov, A.V. Persistence of Reduced Expression of Putative Stem Cell Markers and Slow Wound Healing in Cultured Diabetic Limbal Epithelial Cells. Mol. Vis. 2015, 21, 1357–1367.
  42. Mort, R.L.; Douvaras, P.; Morley, S.D.; Dorà, N.; Hill, R.E.; Collinson, J.M.; West, J.D. Stem Cells and Corneal Epithelial Maintenance: Insights from the Mouse and Other Animal Models. Results Probl. Cell Differ. 2012, 55, 357–394.
  43. Ueno, H.; Ferrari, G.; Hattori, T.; Saban, D.R.; Katikireddy, K.R.; Chauhan, S.K.; Dana, R. Dependence of Corneal Stem/Progenitor Cells on Ocular Surface Innervation. Investig. Ophthalmol. Vis. Sci. 2012, 53, 867–872.
  44. Ponirakis, G.; Abdul-Ghani, M.A.; Jayyousi, A.; Zirie, M.A.; Qazi, M.; Almuhannadi, H.; Petropoulos, I.N.; Khan, A.; Gad, H.; Migahid, O.; et al. Painful Diabetic Neuropathy Is Associated with Increased Nerve Regeneration in Patients with Type 2 Diabetes Undergoing Intensive Glycemic Control. J. Diabetes Investig. 2021, 12, 1642–1650.
  45. Mahelková, G.; Burdová, M.Č.; Malá, Š.; Hoskovcová, L.; Dotřelová, D.; Štechová, K. Higher Total Insulin Dose Has Positive Effect on Corneal Nerve Fibers in DM1 Patients. Investig. Ophthalmol. Vis. Sci. 2018, 59, 3800–3807.
  46. Issar, T.; Tummanapalli, S.S.; Kwai, N.C.G.; Chiang, J.C.B.; Arnold, R.; Poynten, A.M.; Markoulli, M.; Krishnan, A. V Associations between Acute Glucose Control and Peripheral Nerve Structure and Function in Type 1 Diabetes. Diabet. Med. 2020, 37, 1553–1560.
  47. He, J.; Bazan, H.E.P. Mapping the Nerve Architecture of Diabetic Human Corneas. Ophthalmology 2012, 119, 956–964.
  48. Misra, S.L.; Slater, J.A.; McGhee, C.N.J.; Pradhan, M.; Braatvedt, G.D. Corneal Confocal Microscopy in Type 1 Diabetes Mellitus: A Six-Year Longitudinal Study. Transl. Vis. Sci. Technol. 2022, 11, 17.
  49. Yorek, M.S.; Obrosov, A.; Shevalye, H.; Holmes, A.; Harper, M.M.; Kardon, R.H.; Yorek, M.A. Effect of Diet-Induced Obesity or Type 1 or Type 2 Diabetes on Corneal Nerves and Peripheral Neuropathy in C57Bl/6J Mice. J. Peripher. Nerv. Syst. 2015, 20, 24–31.
  50. Yorek, M.S.; Obrosov, A.; Shevalye, H.; Lupachyk, S.; Harper, M.M.; Kardon, R.H.; Yorek, M.A. Effect of Glycemic Control on Corneal Nerves and Peripheral Neuropathy in Streptozotocin-Induced Diabetic C57Bl/6J Mice. J. Peripher. Nerv. Syst. 2014, 19, 205–217.
  51. Davidson, E.P.; Coppey, L.J.; Kardon, R.H.; Yorek, M.A. Differences and Similarities in Development of Corneal Nerve Damage and Peripheral Neuropathy and in Diet-Induced Obesity and Type 2 Diabetic Rats. Investig. Ophthalmol. Vis. Sci. 2014, 55, 1222–1230.
  52. Chen, D.K.; Frizzi, K.E.; Guernsey, L.S.; Ladt, K.; Mizisin, A.P.; Calcutt, N.A. Repeated Monitoring of Corneal Nerves by Confocal Microscopy as an Index of Peripheral Neuropathy in Type-1 Diabetic Rodents and the Effects of Topical Insulin. J. Peripher. Nerv. Syst. 2013, 18, 306–315.
  53. Chan, K.; Badanes, Z.; Ledbetter, E.C. Decreased Corneal Subbasal Nerve Fiber Length and Density in Diabetic Dogs with Cataracts Using in Vivo Confocal Microscopy. Vet. Ophthalmol. 2023, 26, 524–531.
  54. Machet, J.; Park, M.; Richardson, A.; Carnell, M.; Mouat, M.A.; Smith, N.J.; Turner, N.; Cochran, B.J.; Rye, K.A.; Di Girolamo, N. Type 2 Diabetes Influences Intraepithelial Corneal Nerve Parameters and Corneal Stromal-Epithelial Nerve Penetration Sites. J. Diabetes Investig. 2023, 14, 591–601.
  55. Markoulli, M.; Flanagan, J.; Tummanapalli, S.S.; Wu, J.; Willcox, M. The Impact of Diabetes on Corneal Nerve Morphology and Ocular Surface Integrity. Ocul. Surf. 2018, 16, 45–57.
  56. Zhou, T.; Lee, A.; Lo, A.C.Y.; Kwok, J.S.W.J. Diabetic Corneal Neuropathy: Pathogenic Mechanisms and Therapeutic Strategies. Front. Pharmacol. 2022, 13, 816062.
  57. Cosmo, E.; Midena, G.; Frizziero, L.; Bruno, M.; Cecere, M.; Midena, E. Corneal Confocal Microscopy as a Quantitative Imaging Biomarker of Diabetic Peripheral Neuropathy: A Review. J. Clin. Med. 2022, 11, 5130.
  58. Deardorff, P.M.; McKay, T.B.; Wang, S.; Ghezzi, C.E.; Cairns, D.M.; Abbott, R.D.; Funderburgh, J.L.; Kenyon, K.R.; Kaplan, D.L. Modeling Diabetic Corneal Neuropathy in a 3D In Vitro Cornea System. Sci. Rep. 2018, 8, 17294.
  59. Cui, H.; Liu, Y.; Qin, L.; Wang, L.; Huang, Y. Increased Membrane Localization of Pannexin1 in Human Corneal Synaptosomes Causes Enhanced Stimulated ATP Release in Chronic Diabetes Mellitus. Medicine 2016, 95, e5084.
  60. Yang, S.; Zhang, Y.; Zhang, Z.; Dan, J.; Zhou, Q.; Wang, X.; Li, W.; Zhou, L.; Yang, L.; Xie, L. Insulin Promotes Corneal Nerve Repair and Wound Healing in Type 1 Diabetic Mice by Enhancing Wnt/β-Catenin Signaling. Am. J. Pathol. 2020, 190, 2237–2250.
  61. Ponirakis, G.; Abdul-Ghani, M.A.; Jayyousi, A.; Zirie, M.A.; Al-Mohannadi, S.; Almuhannadi, H.; Petropoulos, I.N.; Khan, A.; Gad, H.; Migahid, O.; et al. Insulin Resistance Limits Corneal Nerve Regeneration in Patients with Type 2 Diabetes Undergoing Intensive Glycemic Control. J. Diabetes Investig. 2021, 12, 2002–2009.
  62. He, L.; Hannon, G.J. MicroRNAs: Small RNAs with a Big Role in Gene Regulation. Nat. Rev. Genet. 2004, 5, 522–531.
  63. Diener, C.; Keller, A.; Meese, E. Emerging Concepts of MiRNA Therapeutics: From Cells to Clinic. Trends Genet. 2022, 38, 613–626.
  64. Park, J.K.; Peng, H.; Katsnelson, J.; Yang, W.; Kaplan, N.; Dong, Y.; Rappoport, J.Z.; He, C.; Lavker, R.M. MicroRNAs-103/107 Coordinately Regulate Macropinocytosis and Autophagy. J. Cell Biol. 2016, 215, 667–685.
  65. Wang, L.; Xu, X.; Chen, Q.; Wei, Y.; Wei, Z.; Jin, Z.-B.; Liang, Q. Extracellular Vesicle MicroRNAs From Corneal Stromal Stem Cell Enhance Stemness of Limbal Epithelial Stem Cells by Targeting the Notch Pathway. Investig. Ophthalmol. Vis. Sci. 2023, 64, 42.
  66. Funari, V.A.; Winkler, M.; Brown, J.; Dimitrijevich, S.D.; Ljubimov, A.V.; Saghizadeh, M. Differentially Expressed Wound Healing-Related MicroRNAs in the Human Diabetic Cornea. PLoS ONE 2013, 8, e84425.
  67. Winkler, M.A.; Dib, C.; Ljubimov, A.V.; Saghizadeh, M. Targeting MiR-146a to Treat Delayed Wound Healing in Human Diabetic Organ-Cultured Corneas. PLoS ONE 2014, 9, e114692.
  68. Poe, A.J.; Shah, R.; Khare, D.; Kulkarni, M.; Phan, H.; Ghiam, S.; Punj, V.; Ljubimov, A.V.; Saghizadeh, M. Regulatory Role of MiR-146a in Corneal Epithelial Wound Healing via Its Inflammatory Targets in Human Diabetic Cornea: MiR-146a Inflammatory Role in Diabetic Corneal Epithelial Wound Healing. Ocul. Surf. 2022, 25, 92–100.
  69. Kulkarni, M.; Leszczynska, A.; Wei, G.; Winkler, M.A.; Tang, J.; Funari, V.A.; Deng, N.; Liu, Z.; Punj, V.; Deng, S.X.; et al. Genome-Wide Analysis Suggests a Differential MicroRNA Signature Associated with Normal and Diabetic Human Corneal Limbus. Sci. Rep. 2017, 7, 3448.
  70. Leszczynska, A.; Kulkarni, M.; Ljubimov, A.V.; Saghizadeh, M. Exosomes from Normal and Diabetic Human Corneolimbal Keratocytes Differentially Regulate Migration, Proliferation and Marker Expression of Limbal Epithelial Cells. Sci. Rep. 2018, 8, 15173.
  71. Klocek, M.S.; Sassani, J.W.; McLaughlin, P.J.; Zagon, I.S. Naltrexone and Insulin Are Independently Effective but Not Additive in Accelerating Corneal Epithelial Healing in Type I Diabetic Rats. Exp. Eye Res. 2009, 89, 686–692.
  72. Zagon, I.S.; Sassani, J.W.; McLaughlin, P.J. Insulin Treatment Ameliorates Impaired Corneal Reepithelialization in Diabetic Rats. Diabetes 2006, 55, 1141–1147.
  73. Aynsley, T.R. The use of insulin in the treatment of corneal ulcers. Br. J. Ophthalmol. 1945, 29, 361–363.
  74. Fai, S.; Ahem, A.; Mustapha, M.; Mohd Noh, U.K.; Bastion, M.-L.C. Randomized Controlled Trial of Topical Insulin for Healing Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics. Asia-Pac. J. Ophthalmol. 2017, 6, 418–424.
  75. Dasrilsyah, A.M.; Wan Abdul Halim, W.H.; Mustapha, M.; Tang, S.F.; Kaur, B.; Ong, E.Y.; Catherine Bastion, M.L. Randomized Clinical Trial of Topical Insulin Versus Artificial Tears for Healing Rates of Iatrogenic Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics. Cornea 2023, 42, 1395–1403.
  76. Balal, S.; Din, N.; Ashton, C.; Ahmad, S. Healing of Chemical Injury-Related Persistent Corneal Epithelial Defects With Topical Insulin. Cornea 2022, 42, 1000–1004.
  77. Diaz-Valle, D.; Burgos-Blasco, B.; Gegundez-Fernandez, J.A.; Garcia-Caride, S.; Puebla-Garcia, V.; Peña-Urbina, P.; Benitez-del-Castillo, J.M. Topical Insulin for Refractory Persistent Corneal Epithelial Defects. Eur. J. Ophthalmol. 2021, 31, 2280–2286.
  78. Esmail, A.; Ibrahim, M.; Nage, S. Efficacy of Topical Insulin for Recurrent Epithelial Corneal Erosions. Ir. J. Med. Sci. 2023, 192, 3117–3123.
  79. Soares, R.J.D.S.M.; Arêde, C.; Sousa Neves, F.; da Silva Fernandes, J.; Cunha Ferreira, C.; Sequeira, J. Topical Insulin-Utility and Results in Refractory Neurotrophic Keratopathy in Stages 2 and 3. Cornea 2022, 41, 990–994.
  80. Diaz-Valle, D.; Burgos-Blasco, B.; Rego-Lorca, D.; Puebla-Garcia, V.; Perez-Garcia, P.; Benitez-Del-Castillo, J.M.; Herrero-Vanrell, R.; Vicario-de-la-Torre, M.; Gegundez-Fernandez, J.A. Comparison of the Efficacy of Topical Insulin with Autologous Serum Eye Drops in Persistent Epithelial Defects of the Cornea. Acta Ophthalmol. 2022, 100, e912–e919.
  81. Wang, A.L.; Weinlander, E.; Metcalf, B.M.; Barney, N.P.; Gamm, D.M.; Nehls, S.M.; Struck, M.C. Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers. Cornea 2017, 36, 1426–1428.
  82. Bastion, M.L.C.; Ling, K.P. Topical Insulin for Healing of Diabetic Epithelial Defects?: A Retrospective Review of Corneal Debridement during Vitreoretinal Surgery in Malaysian Patients. Med. J. Malays. 2013, 68, 208–216.
  83. Burgos-Blasco, B.; Diaz-Valle, D.; Rego-Lorca, D.; Perez-Garcia, P.; Puebla-Garcia, V.; Fernandez-Vigo, J.I.; Benitez-Del-Castillo, J.M.; Gegundez-Fernandez, J.A. Topical Insulin, a Novel Corneal Epithelial Regeneration Agent in Dry Eye Disease. Eur. J. Ophthalmol. 2023, 11206721231206790.
  84. Serrano-Giménez, R.; Contreras-Macías, E.; García-Bernal, A.; Fobelo-Lozano, M.J. Insulina Tópica En El Tratamiento de Úlcera Corneal Refractaria En Un Paciente No Diabético: A Propósito de Un Caso. Farm. Hosp. 2020, 44, 297–299.
  85. Tong, C.M.; Iovieno, A.; Yeung, S.N. Topical Insulin for Neurotrophic Corneal Ulcers. Can. J. Ophthalmol. 2020, 55, e170–e172.
  86. Galvis, V.; Niño, C.A.; Tello, A.; Grice, J.M.; Gómez, M.A. Topical Insulin in Neurotrophic Keratopathy after Resection of Acoustic Neuroma. Arch. Soc. Esp. Oftalmol. 2019, 94, 100–104.
  87. Giannaccare, G.; Coco, G.; Rossi, C.; Borselli, M.; Lucisano, A.; Vaccaro, S.; Verdiglione, M.; Scorcia, V. Combined Use of Therapeutic Hyper-CL Soft Contact Lens and Insulin Eye Drops for the Treatment of Recalcitrant Neurotrophic Keratopathy. Cornea 2023, 43, 120–124.
  88. Khilji, M.; Tanveer, S.; Khan, F.Z.; Yazdan, D.A.; Khilji, A. Neurotrophic Keratopathy and Topical Insulin Therapy: A Case Report. Cureus 2023, 15, 7–11.
  89. Anitua, E.; de la Fuente, M.; Sánchez-Ávila, R.M.; de la Sen-Corcuera, B.; Merayo-Lloves, J.; Muruzábal, F. Beneficial Effects of Plasma Rich in Growth Factors (PRGF) Versus Autologous Serum and Topical Insulin in Ocular Surface Cells. Curr. Eye Res. 2023, 48, 456–464.
  90. Castro Mora, M.P.; Palacio Varona, J.; Perez Riaño, B.; Laverde Cubides, C.; Rey-Rodriguez, D.V. Effectiveness of Topical Insulin for the Treatment of Surface Corneal Pathologies. Arch. La Soc. Española Oftalmol. 2023, 98, 220–232.
  91. Jaworski, M.; Lorenc, A.; Leszczyński, R.; Mrukwa-Kominek, E. Topical Insulin in Neurotrophic Keratopathy: A Review of Current Understanding of the Mechanism of Action and Therapeutic Approach. Pharmaceutics 2023, 16, 15.
  92. Cruz-Cazarim, E.L.C.; Cazarim, M.S.; Ogunjimi, A.T.; Petrilli, R.; Rocha, E.M.; Lopez, R.F. V Prospective Insulin-Based Ophthalmic Delivery Systems for the Treatment of Dry Eye Syndrome and Corneal Injuries. Eur. J. Pharm. Biopharm. 2019, 140, 1–10.
  93. Voronova, A.; Prieto, C.; Pardo-Figuerez, M.; Lagaron, J.M.; Sanyal, A.; Demir, B.; Hubert, T.; Plaisance, V.; Pawlowski, V.; Vignoud-Despond, S.; et al. Photothermal Activatable Mucoadhesive Fiber Mats for On-Demand Delivery of Insulin via Buccal and Corneal Mucosa. ACS Appl. Bio. Mater. 2022, 5, 771–778.
  94. Liao, Y.; Jiang, H.; Du, Y.; Xiong, X.; Zhang, Y.; Du, Z. Using Convolutional Neural Network as a Statistical Algorithm to Explore the Therapeutic Effect of Insulin Liposomes on Corneal Inflammation. Comput. Intell. Neurosci. 2022, 2022, 1169438.
  95. Xiong, X.; Jiang, H.; Liao, Y.; Du, Y.; Zhang, Y.; Wang, Z.; Zheng, M.; Du, Z. Liposome–Trimethyl Chitosan Nanoparticles Codeliver Insulin and SiVEGF to Treat Corneal Alkali Burns by Inhibiting Ferroptosis. Bioeng. Transl. Med. 2023, 8, e10499.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , ,
View Times: 60
Revisions: 2 times (View History)
Update Date: 04 Mar 2024
1000/1000